Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ipsen Gives Genfit Liver Drug New Lease Of Life

Pays €120m Upfront For Elafibranor Rights

Dec 17 2021

• By Kevin Grogan

liver — • Source: Archive

Related Content

Intercept Drug’s Market Standing In PBC Undermined By Safety Woes

May 27 2021

CymaBay Builds Seladelpar Case In PBC, But Door Not Closed On NASH

Jun 30 2021

Further Analyses To Delay Ipsen’s Palovarotene Progress In Ultra-Rare Disease

Aug 13 2021

RESOLVE-IT Failure Dashes Genfit's NASH Hopes

May 12 2020

Related Companies

Genfit SA

Ipsen SA

Intercept Pharmaceuticals, Inc.

CymaBay Therapeutics, Inc.

Genoscience Pharma

Additional Topics

Companies Deals Commercial Rare Diseases Liver & Hepatic BioPharmaceutical

More from Alimentary/Metabolic

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.